Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Daclizumab - AbbVie/Biogen

Drug Profile

Daclizumab - AbbVie/Biogen

Alternative Names: BIIB-019; DAC HYP; Dacliximab; Daclizumab high-yield process; Daclizumab HYP; HAT antibody; Humanised anti-Tac antibody; R35; RO 247375; SMART anti-Tac antibody; Zenapax; Zinbryta

Latest Information Update: 20 Dec 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PDL BioPharma
  • Developer AbbVie; Biogen; Dana-Farber Cancer Institute; National Cancer Institute (USA); PDL BioPharma
  • Class Antiasthmatics; Antihyperglycaemics; Monoclonal antibodies
  • Mechanism of Action Immunosuppressants; Interleukin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Renal transplant rejection
  • Phase III Multiple sclerosis
  • Discontinued Asthma; Graft-versus-host disease; Haematological malignancies; Immune-mediated uveitis; Liver transplant rejection; Psoriasis; Tropical spastic paraparesis; Type 1 diabetes mellitus; Ulcerative colitis

Most Recent Events

  • 22 Nov 2018 Biogen and AbbVie terminates phaseIII trial in Multiple Sclerosis in Argentina, Australia, Brazil, Canada, Czech Republic, Denmark, England, Finland, France, Georgia, Germany, Greece, Hungary, India, Ireland, Israel, Italy, Mexico, Moldova, Multinational, Poland, Romania, Russia, Scotland, Senegal, Serbia, Spain, Sweden, Switzerland, Ukraine, United Kingdom, USA (NCT01797965)
  • 15 Sep 2018 Discontinued - Phase-III for Multiple sclerosis (Recurrent) in Puerto Rico (SC) (NCT02881567)
  • 15 Sep 2018 Biogen and AbbVie terminates the phase IIIb SUSTAIN trial for Multiple sclerosis in Germany, United Kingdom, USA, Canada, Italy, Puerto Rico due to Biogen's decision to withdraw Zinbryta from the market (NCT02881567)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top